The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.

What Was Tested

Researchers studied Gonadorelin in this clinical trial publication.

The fertility rate in women with polycystic ovary disease (PCOD) is influenced by the type of treatment received.

The present study evaluated the possible correlation between treatment and pulsatile release of gonadotropins.

Who Took Part

According to the abstract, 12 subjects were involved.

PubMed tags the participants as women only.

Spontaneous episodic secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and hormonal parameters were monitored before and after 1, 3, and 6 months after treatments suspension.

Twenty-four PCOD patients were randomly divided into two groups of 12 subjects.

How the Study Was Run

The design is described as randomized.

The subjects were allocated by chance, so the Gonadorelin group and the comparison group should start out alike.

Group A was treated with gonadotropin-releasing hormone (GnRH)-analogue plus oral contraceptive (OC).

Group B was treated only with OC.

What Was Measured

The subject headings attached to it are 17-alpha-Hydroxyprogesterone, Androstenedione, Bone Density, Contraceptives, Oral, Estradiol, Follicle Stimulating Hormone and Gonadotropin-Releasing Hormone.

What This Means in Plain Language

The paper is a randomized study of Gonadorelin in 12 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Journal of assisted reproduction and genetics), a journal based in Netherlands.

More context: the Gonadorelin compound page, all human trials.